Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
YAZ · 5 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Arm 1 | ACTIVE_COMPARATOR | - |
| Arm 2 | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| YAZ (SH T00186, BAY86-5300) | DRUG | 20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd |
| YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300) | DRUG | Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles |
| Placebo | DRUG | The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle) |
| Yasminelle (SH T 00186 D) | DRUG | SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each |
Inclusion Criteria: * Healthy women between 18 and 45 requesting oral contraception. * Smokers may not exceed 30 years of age. Exclusion Criteria: * The use of steroidal oral contraceptives , or any drug that could alter oral contraception metabolism will be prohibited during the study. * Pregnan...
YAZ is an oral contraceptive used for contraception and for the treatment of acne vulgaris. It is a small molecule developed by Bayer AG. Clinical trials have evaluated YAZ in women for contraception and in women with moderate acne, with completed Phase 3 studies in both indications.
YAZ is developed by Bayer AG, a company traded under the ticker BAYRY. Bayer has conducted clinical trials for YAZ in contraception and acne vulgaris, including studies in the United States, China, Hong Kong, and the Netherlands.
YAZ is in Phase 3 clinical development. It has completed Phase 3 trials for contraception and acne vulgaris. YAZ is investigational and still in clinical development, with no indication that it is FDA approved based on the available data.
YAZ has completed several clinical trials, including NCT00185484 for contraception with 1113 participants, NCT00651469 for moderate acne with 534 participants, and NCT00819312 for contraception in China with 675 participants. A Phase 2 trial, NCT00673686, studied missed pills and follicular development.
YAZ is associated with the study drug SH T 00186 D, which was evaluated in a clinical trial for oral contraceptives. The trial NCT00673686 investigated the effect of missed pills on follicular development in two application regimens of SH T 00186 D.